Bioxcel Therapeutics Wins Approval From The U.S. Patent And Trademark Office For A Patent Application Related To The Use Of Sublingual Dexmedetomidine For The Treatment Of Agitation
Portfolio Pulse from Benzinga Newsdesk
Bioxcel Therapeutics has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application related to the use of sublingual dexmedetomidine for the treatment of agitation. The company plans to list the patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations for IGALMI. The patent is expected to expire no earlier than December 29, 2037.
September 12, 2023 | 11:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bioxcel Therapeutics' patent approval for a treatment of agitation could potentially boost its market position and revenue in the long term.
The approval of the patent application by the USPTO is a significant milestone for Bioxcel Therapeutics. It not only validates the company's research and development efforts but also provides it with exclusive rights to manufacture and sell the treatment for agitation. This could potentially lead to increased revenue and a stronger market position. However, the actual impact will depend on the market acceptance of the treatment and the competitive landscape.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100